Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Antonio Rodriguez

Pediatric Pulmonology Miami, FL Medical Doctor

NPI 1508839408 CMS profile 747969

3200 Sw 60Th Ct, Suite 203, Miami, FL 33155

Open in the dashboard

General payments

$1,448

59 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Antonio Rodriguez of Miami, FL is reported in the CMS Open Payments database as having received $1,448 across 59 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Pediatric Pulmonology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $46 2
2024 General $118 6
2023 General $179 7
2022 General $248 11
2021 General $365 13
2020 General $176 9
2019 General $318 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Antonio Rodriguez
  • Pediatric Pulmonology median
  • Middle half of Pediatric Pulmonology
  • National median

In program year 2025, general payments to Antonio Rodriguez were reported at $46. Among 622 Pediatric Pulmonology profiles paid that year, the median was $139 and the middle half received between $60 and $405.

Show as a table
Year Antonio Rodriguez Pediatric Pulmonology median Middle half National median
2019 $318 $151 $59–$495 $163
2020 $176 $107 $34–$339 $114
2021 $365 $125 $40–$511 $132
2022 $248 $133 $49–$428 $149
2023 $179 $138 $44–$494 $160
2024 $118 $132 $46–$398 $164
2025 $46 $139 $60–$405 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $332 17 payments
  2. Sobi, Inc $306 11 payments
  3. Baxter Healthcare $159 8 payments
  4. GlaxoSmithKline, LLC. $147 2 payments
  5. AstraZeneca Pharmaceuticals LP $107 1 payment
  6. Advanced Respiratory, Inc $95 5 payments
  7. Nestle HealthCare Nutrition Inc. $69 4 payments
  8. Genzyme Corporation $44 2 payments
  9. Philips Electronics North America Corporation $41 2 payments
  10. Aimmune Therapeutics, Inc. $40 2 payments
  11. Other $107 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,448 59 payments
Products named General payments · program years 2019–2025
  1. SYNAGIS $306 11 payments
  2. CREON $293 15 payments
  3. NUCALA $147 2 payments
  4. ZENPEP $109 6 payments
  5. FARXIGA $107 1 payment
  6. Hillrom - Vest System Model 105 Home Care $84 4 payments
  7. Hillrom - Volara System $53 3 payments
  8. DUPIXENT $44 2 payments
  9. The Vest System Model 105 Home Care $36 2 payments
  10. Brinsupri $24 1 payment
  11. Other $250 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 78 drugs

Part D claims

3,433

Median for Pediatric Medicine: 38

Drug cost

$241,305

Median for Pediatric Medicine: $2,769

Branded share of claims

15.8%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluticasone Propionate Hfa Fluticasone Propionate Brand 127 $32,772
Eliquis Apixaban Brand 39 $24,779
Linzess Linaclotide Brand 43 $24,473
Lactulose Generic 142 $13,274
Scopolamine Generic 86 $12,963
Lansoprazole Generic 31 $12,473
Sucralfate Generic 55 $11,784
Advair Hfa Fluticasone Propion/Salmeterol Brand 30 $10,168
Methenamine Hippurate Generic 117 $9,517
Symbicort Budesonide/Formoterol Fumarate Brand 37 $8,446

The 10 drugs with the highest cost, of 78 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
  • AbbVie, Inc. $21
$21 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

59 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Pulmonology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record